Payment overview · 2025
General Payments
$561.48
25 reported records · 14 companies
Healthcare provider profile · identity verified
Jason H Smith, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ATLANTA, GA · NPI 1407937899
Verified facts
What the public records show
CMS Open Payments records show Jason H Smith, MD received $561.48 in general payments during 2025 across 25 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $123.95 | 22.1% | 6 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $63.51 | 11.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.38 | 9.2% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $50.68 | 9.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.26 | 8.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $42.54 | 7.6% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $27.38 | 4.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.19 | 4.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $26.06 | 4.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.04 | 4.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.24 | 3.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.22 | 3.6% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.53 | 3.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.50 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $561.48 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $123.95 | 6 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $51.38 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $51.38 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $50.68 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $48.26 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $48.26 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $42.54 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.19 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.19 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $26.06 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $26.04 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 496 | 147 |
| Losartan Potassium | Losartan Potassium | 320 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 305 | 87 |
| Lisinopril | Lisinopril | 156 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 145 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 144 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 120 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 33 |
| Metformin Hcl | Metformin Hcl | 103 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 22 |
| Omeprazole | Omeprazole | 101 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 32 |
| Simvastatin | Simvastatin | 92 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 91 | 27 |
| Sertraline Hcl | Sertraline Hcl | 80 | 20 |
| Metformin Hcl Er | Metformin Hcl | 74 | 24 |
| Atenolol | Atenolol | 72 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 25 |
| Ozempic | Semaglutide | 64 | suppressed |
| Alprazolam | Alprazolam | 63 | 23 |
| Gabapentin | Gabapentin | 59 | 19 |
| Trazodone Hcl | Trazodone Hcl | 54 | 17 |
| Allopurinol | Allopurinol | 52 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 17 |
| Glimepiride | Glimepiride | 47 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 12 |
| Meloxicam | Meloxicam | 45 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 14 |
| Ezetimibe | Ezetimibe | 43 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | 13 |
| Furosemide | Furosemide | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 25 |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Minoxidil | Minoxidil | 27 | suppressed |
| Carvedilol | Carvedilol | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Baclofen | Baclofen | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $561.48 · 25 records | SANOFI-AVENTIS U.S. LLC | AREXVY, GEMTESA, INSPIRE, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, PYRUKYND, QULIPTA, SAPIEN 3 Ultra RESILIA, SHINGRIX, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, XIFAXAN, ZAVZPRET, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error